DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...

A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Stelo CGM Launch: In August 2024, DexCom announced the commercial launch of Stelo CGM, the first over-the-counter glucose sensor in the U.S. for non-insulin using Type 2 diabetes and prediabetes ...

Any time we try a healthy new way of eating, it’s easy for doubt to creep in. Is it really working? Is it worth it? Does it ...

Dexcom also provided continuous glucose monitoring sensors at a discounted rate for this study. Note to editors: The author(s) declared the following potential conflicts of interest with respect ...

not a long-term thing that we will have to do because we see that if they have that CGM on, it’s more reliable,” said Dr. Bruner-Hill In a post on Dexcom’s website, the company said if you are unable ...

DexCom, Inc. (NASDAQ ... systems for people with diabetes. Its CGM devices provide real-time glucose readings through a sensor, transmitter, and mobile app, eliminating the need for traditional ...